Results 191 to 200 of about 22,306,541 (256)

Pharmacokinetics of intraperitoneal mitomycin C

Surgical Oncology Clinics of North America, 2003
The favorable pharmacokinetics of MMC, used during intraperitoneal chemotherapy, has been reported in several studies [11-19]. A major safety issue in studies using intraperitoneal chemotherapy perfusion is the resulting systemic drug exposure. The AUCplasma is determined by the dose, the clearance, and the fraction absorbed from the peritoneal cavity.
S, van Ruth, V J, Verwaal, F A, Zoetmulder   +2 more
openaire   +2 more sources

Intraoperative Mitomycin C in Dacryocystorhinostomy

Ophthalmic Plastic and Reconstructive Surgery, 2001
To assess the efficacy of intraoperative mitomycin C (MMC) in external dacryocystorhinostomy (EXT-DCR).Forty-six cases (50 lacrimal drainage systems [LDS]) with nasolacrimal duct obstruction were randomized into three groups. In the control group, a standard EXT-DCR procedure was performed. In the two MMC groups, a piece of cotton soaked with 0.2 mg/ml
Y A, You, C T, Fang
openaire   +2 more sources

Reductive activation of mitomycin C

Biochemistry, 1988
Mitomycin C, an antitumor antibiotic, is known to require reductive activation in order to function as an alkylating agent. In this work reduction has been carried out by using radiolytically produced formate radicals that reduce mitomycin C to its semiquinone in a clean rapid one-electron reaction.
B M, Hoey, J, Butler, A J, Swallow
openaire   +2 more sources

Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.

European Journal of Surgical Oncology, 2017
V. Leung, Ya Ruth Huo, W. Liauw, David G. Morris, D. L. Morris   +4 more
semanticscholar   +1 more source

CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-κB pathway.

Biochemical and Biophysical Research Communications - BBRC, 2018
Chanjuan Wang, Aiwei Li, Shuo Yang, Rui Qiao, Xi Zhu, Jie Zhang   +5 more
semanticscholar   +1 more source

Current treatment and future directions in the management of anal cancer

Ca-A Cancer Journal for Clinicians, 2022
Leila T Tchelebi, Cathy Eng, Craig A Messick   +2 more
exaly  

Mitomycin C

Cold Spring Harbor Protocols, 2006
  +4 more sources

Molecularly imprinted cryogel membranes for mitomycin C delivery

Journal of Biomaterials Science. Polymer Edition, 2017
Pınar Öncel, Kemal Çetin, A. A. Topçu, H. Yavuz, A. Denizli   +4 more
semanticscholar   +1 more source

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non‐muscle‐invasive bladder cancer

BJU International, 2016
Patrick A. Cockerill, J. Knoedler, I. Frank, R. Tarrell, R. Karnes   +4 more
semanticscholar   +1 more source

Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.

Journal of Urology, 2016
C. Gan, S. Amery, K. Chatterton, Muhammad S. Khan, K. Thomas, T. O'brien   +5 more
semanticscholar   +1 more source